Pathological Complete Response Of Neo-adjuvant Chemotherapy Doxorubicin Plus Cyclophosphamide In Patients With Locally Advanced Breast Cancerat Jinnah Hospital Lahore

Abstract

Objective: Objective of the study was to determine the frequency of pathological complete
response (pCR) with neo adjuvant doxorubicin and cyclophosphamide in locally advanced breast
cancer.
Material and Methods: This prospective study was conducted in 92 patients of locally
advanced breast cancer. Pathological response was evaluated on Modified radical mastectomy
samples that was performed after 4 cycles of neo adjuvant doxorubicin and cyclophosphamide.
Results: The mean age of the study population was 45.63 year.Among these the 49.63( 38%)
had stage T3 lesion , 53(57.6) had T4 and only one patient (1.1%) with T1 at presentation. 97.8
(92%) patients were with grade 2 and grade 3.Post anthracycline based NACT 8.7 %(8) had
pathological complete response, 54.3 %( 50 ) had partial response, 37%( 34) had stable disease.
Overall 63% (58) patients had responded to this treatment.
Conclusion: It is concluded from the this study that Anthracycline based NACT is a good option
for these patients of developing countries. Though the results are not comparable with developed
countries but better results can be achieved if these patients present at early stage or we should
use taxanes based NACTto improve the response.